Table 1.
The main features of the studies included the analysis of SII and outcome measures in CRC patients. The “Histology” column specifies whether the study focuses on colorectal cancer (CRC), colon cancer, rectal cancer, or liver metastases specific to colon or rectal cancer (CLM or RLM, respectively). The column “Study design” refers to the prospective (prospect) or retrospective (retrospect) nature of the study.
| First Author | Year | Country | Histology | Study Period | Study Design | Sample Size | Age (Median) | Sex M/F |
TNM Stage |
Treatment | SII Cutoff |
Method for Cutoff Selection | Follow-Up (Months) | Survival Endpoint |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Passardi [32] | 2016 | Italy | CRC | 2007–2012 | prospect | 289 | 65.5 | 174/115 | I–IV | chemo + targeted therapy | 730 | X-tile | 36 (1–65) |
OS PFS |
| Chen [26] | 2017 | China | CRC | 1994–2010 | retrospect | 1383 | NA | 788/595 | I–IV | surgical resection | 340 | ROC analysis |
NA | OS PFS |
| Yang [41] | 2017 | China | CRC | 2009–2015 | retrospect | 95 | 57 | 58/37 | IV | chemo + targeted therapy | 460.7 | median | 40 (12–72) |
OS PFS |
| Xie [39] | 2018 | China | CRC | 2009–2014 | retrospect | 240 | 59 (18–90) |
157/83 | IV | surgical resection | 649.5 | median | 26.7 (1.1–92.4) |
OS |
| Tao [36] | 2018 | China | colon | 2011–2013 | retrospect | 118 | 60 | 63/55 | I–IV | surgical resection | 667.8 | median | 36 | OS |
| Yang [42] | 2018 | China | CRC | 2010–2015 | retrospect | 98 | 53 (26–83) |
59/39 | I–IV | neoadjuvant chemo-radiotherapy | 437.7 | median | 37 (16.2–93.3) |
OS PFS |
| Zhou [53] | 2018 | China | CRC | 2007–2015 | retrospect | 516 | 16–87 | 331/185 | I–IV | surgical resection | 568.7 | ROC analysis |
21.7 (2.1–118.7) |
OS PFS |
| Wang [37] | 2019 | China | CRC | 2002–2016 | retrospect | 452 | 57 | 289/163 | IV | surgical resection | 517 | X-tile | 28 | OS PFS |
| Yang [43] | 2019 | China | CRC | 2009–2015 | retrospect | 220 | 57 | 133/87 | III–IV | adjuvant chemo-radiotherapy | 534.9 | ROC analysis |
23.9 (12–87) |
OS PFS |
| Zhang [52] | 2019 | China | CRC | 2010–2013 | retrospect | 224 | 67 (30–89) |
127/97 | I–IV | surgical resection | 642.2 | median | 48 | OS |
| Jiang [30] | 2020 | China | CRC | 2010–2017 | retrospect | 102 | 28–75 | 72/30 | IV | chemo + targeted therapy | 660.6 | ROC analysis |
33.2 (2.6–94.5) |
OS PFS |
| Yan [40] | 2020 | China | CRC | 1997–2013 | retrospect | 103 | 47 over 60 | 67/46 | III–IV | surgery + chemotherapy | 410 | ROC analysis |
55.4 | OS |
| Yatabe [44] | 2020 | Japan | CRC | 2010–2014 | retrospect | 733 | 66 (58–74) |
463/270 | I–IV | surgical resection | median 550 | SII trichotomized into tertiles | 36 60 | OS |
| Deng [28] | 2021 | China | CRC | 2006–2016 | retrospect | 283 | 57 (25–82) |
187/96 | I–IV | surgery + chemotherapy | 0.0135 | ROC analysis |
35.4 | OS RFS |
| Ying [46] | 2021 | China | CRC | 2013–2016 | retrospect | 1014 | 460 over 60 | 622/392 | II–III | surgery + chemotherapy | 665 | X-tile | 36 | RFS |
| Ying [46] | 2021 | China | CRC | 2013–2016 | retrospect | 519 | 328 over 60 | 622/392 | II–III | surgery + chemotherapy | 665 | X-tile | 36 | RFS |
| Guan [29] | 2022 | China | rectal | 2016–2019 | retrospect | 278 | 53.97 ± 10.11 | 181/97 | II–IV | neoadjuvant chemo-radiotherapy | 540 | X-tile | Last follow-up: 31 December 2021 |
OS DFS |
| Jin [31] | 2022 | China | CRC | 2012–2015 | retrospect | 476 | 60.8 (25–90) |
259/217 | I | surgical resection | 540.3 | ROC analysis |
68 | OS DFS |
| Polk [25] | 2022 | Hungary | CRC colon (CLM) | 2001–2018 | retrospect | 67 | 65 | 36/31 | IV | surgery + chemotherapy | 535/290 RFS/OS | ROC analysis |
46.5 | OS RFS |
| Polk [25] | 2022 | Hungary | CRC renal (RLM) | 2001–2018 | retrospect | 103 | 62 | 69/34 | IV | surgery + chemotherapy | 792/742 RFS/OS | ROC analysis |
59.8 | OS RFS |
| Passardi [33] | 2023 | Italy | CRC | 2016–2019 | prospect | 182 | 33–83 | 72/60 | I–IV | chemo + targeted therapy | 730 | ROC analysis |
52.6 | OS PFS |
| Chiloiro [27] | 2023 | Italy | rectal | 2002–2019 | retrospect | 808 | 64 (26–88) |
493/315 | I–IV | neoadjuvant chemo-radiotherapy | 500 | log-rank test | 53.5 (range 6–198) |
OS DFS |
| Sato [34] | 2023 | Japan | CRC | 2013–2020 | retrospect | 86 | 71 (37–93) |
50/36 | II–IV | surgical resection | 597 | ROC analysis |
35 | RFS |
| Xiang [38] | 2023 | China | CRC | 2013–2017 | retrospect | 236 | 45 | 143/93 | I–III | neoadjuvant chemo-radiotherapy, adjuvant therapy | 637.6 | survminer R package | 48 | OS |
| Yi [45] | 2023 | China | CRC | 2017–2021 | retrospect | 75 | 47 (23–84) |
48/27 | IV | chemo+ immuno-therapy | 409.6 | ROC analysis |
24 | OS PFS |
| Young [47] | 2023 | USA | CRC | 2014–2019 | retrospect | 41 | 61.4 ± 8.2 | 21/20 | IV | transarterial radio-embolization (TARE), chemotherapy | 591.7 | median | 12 | OS PFS |
| Zhang [50] | 2023 | China | colon | 2013–2018 | retrospect | 188 | 67 (33–92) |
117/71 | I–IV | surgical resection | 514.1 | median | 43 | DFS |
| Zhang [49] | 2023 | China | CRC | 2019–2023 | retrospect | 160 | 64 (38–85) |
98/62 | I–IV | surgical resection | 513.5 | ROC analysis |
29.25 (2–60) |
OS |